Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease - News-Medical.Net

Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg ...

Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio - Yahoo Finance

Treatment consists of the protein pump inhibitor omeprazole and two broad spectrum antibiotics; clarithromycin tablets and amoxicillin capsules. The medications are to be taken together, twice daily, for ten days.  "We have recruited a new ...

Popular Antibiotic May Raise Risk of Sudden Death - New York Times

Two related antibiotics, erythromycin and clarithromycin, were already known to raise the risk of sudden death. But azithromycin was thought to be safer. Experts outside the study gave it differing reviews. Dr. John G. Bartlett, a professor of ...

FDA to Review CV Risk With Azithromycin After NEJM Study - Medscape News

That class, called macrolides, also includes clarithromycin (Biaxin, Abbott) and erythromycin, neither of which figured into the NEJM study. Azithromycin (Zithromax) Patients taking azithromycin should not stop taking it without consulting a ...

Omeclamox-Pak Available for Treating H. pylori - Monthly Prescribing Reference

Pernix Therapeutics Holdings has introduced Omeclamox-Pak, a ten-day therapy of omeprazole delayed-release capsules (20mg), clarithromycin tablets (500mg) and amoxicillin capsules (500mg) for the treatment of Helicobacter pylori (H. pylori) infection and ...

Common antibiotic linked to risk of sudden death, study finds - McKnight's

Azithromycin, which is frequently referred to as a “Z-Pak,” was generally believed to be safer than antibiotics such as erythromycin and clarithromycin. Previous studies have linked erythromycin with a higher risk for heart attack. However, when ...

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA - Newsinferno.com

Other antibiotics in this class include clarithromycin (Biaxin) and erythromycin. According to the agency, the “Warnings and Precautions” section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March ...

FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death - Center for Food Safety and Applied Nutrition

Azithromycin was the only macrolide examined in the published study; the study did not address other macrolide antibacterial drugs, such as clarithromycin (Biaxin) and erythromycin, regarding the potential for cardiovascular death. In 2011, FDA reviewed ...

Azithromycin may increase risk of sudden death - Presstv

Two related antibiotics, erythromycin and clarithromycin, were already known to increase the risk of sudden death. But azithromycin was thought to be safer. The scientists suggest that azithromycin may cause irregular heartbeats or arrhythmias, a condition ...

Zithromax (azithromycin): FDA Statement on risk of cardiovascular death - Center for Food Safety and Applied Nutrition

The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.